Bahrain Confirms Sputnik V Vaccination Efficacy

The Russian Direct Investment Fund (RDIF) announced on June 10, 2021, the Ministry of Health of the Kingdom of Bahrain collected data between February and early May 2021 following World Health Organization guidelines involving more than 5,000 subjects.

This new Sputnik V vaccine effectiveness analysis found an overall efficacy beyond 14 days after administering the second vaccine dose was estimated at 94.3%.

Bahrain data also demonstrates that 98.6% of all COVID-19 cases 14 days after receiving the second dose were mild among those vaccinated with Sputnik V.

From a safety perspective, the data indicates Sputnik V vaccination generated no serious adverse events associated with vaccination, no deaths related to the vaccination, no cerebral vein thrombosis cases after vaccination.

HE Faeqa Saeed Al-Saleh, Bahrain’s Minister of Health, stated in an RDIF press release, “Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain."

"This vaccine is one of several Approved vaccines made available free of charge to citizens and residents in the Kingdom. Sputnik V continues to play an important role in the Kingdom’s ongoing and successful vaccination campaign, with 81% of the eligible population vaccinated so far.”

The Russian Direct Investment Fund is a sovereign wealth fund established in 2011 to make equity co-investments.